Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. (Q34169978)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

review article

1 reference

title

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

0 references

0 references

1 reference

Adrian Newman-Tancredi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Mark S Kleven

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

11 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

451-473

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00213-011-2247-y

25 January 2020

exact match

0 references

cites work

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Do we still believe in the dopamine hypothesis? New data bring new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The serotonin-1A receptor in anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Occupancy of agonist drugs at the 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

A review of central 5-HT receptors and their function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Serotonergic regulation of membrane potential in developing rat prefrontal cortex: coordinated expression of 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT7 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Dopamine agonists in schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Is there a role for 5-HT1A agonists in the treatment of depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The antipsychotic potential of muscarinic allosteric modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

[3H]WAYâ 100635 for 5â HT1A receptor autoradiography in human brain: a comparison with [3H]8â OHâ DPAT and demonstration of increased binding in the frontal cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The 5-HT(1A) receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Cognitive inflexibility after prefrontal serotonin depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The efficiency of multi-target drugs: the network approach might help drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Searching for schizophrenia in ancient Greek and Roman literature: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The impact of drug-induced QT interval prolongation on drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Estrogen prevents 5-HT1A receptor-induced disruptions of prepulse inhibition in healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Human Freud-2/CC2D1B: a novel repressor of postsynaptic serotonin-1A receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effectiveness of second-generation antipsychotics with acute-phase schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The dopamine hypothesis of schizophrenia: version III--the final common pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Pathways to schizophrenia: the impact of environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Serotonergic approaches in the development of novel antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Half a century of antipsychotics and still a central role for dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Relapse prevention with gepirone ER in outpatients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Functional selectivity and biased receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

PET tracers for 5-HT(1A) receptors and uses thereof

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Optimisation of anti-psychotic therapeutics: a balancing act?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Transcriptional regulation at a HTR1A polymorphism associated with mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Provocative tests with psychostimulant drugs in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Cognition, schizophrenia, and the atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Cardiovascular effects of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Atypical Antipsychotics in First Admission Schizophrenia: Medication Continuation and Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The role of 5-HT(1A) receptors in learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effects of serotonin-dopamine antagonists on prepulse inhibition and neurotransmitter contents in the rat cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Behavioral indices in antipsychotic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Clozapine and global cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Size of burden of schizophrenia and psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Perospirone, a Novel Antipsychotic Agent, Hyperpolarizes Rat Dorsal Raphe Neurons via 5-HT1A Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Working memory deficit as a core neuropsychological dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Comparative effects of d-amphetamine, l-amphetamine and methylphenidate on mood in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effects of selective 5-HT1A receptor antagonists on regional serotonin synthesis in the rat brain: an autoradiographic study with alpha-[14C]methyl-L-tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

The presynaptic component of the serotonergic system is required for clozapine's efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

Schizophrenia: the fundamental questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2247-Y

[3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia

21 January 2018

1 reference

12 December 2020

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse

1 reference

12 December 2020

Methylphenidate challenge as a predictor of relapse in schizophrenia

1 reference

12 December 2020

Should cognitive deficit be a diagnostic criterion for schizophrenia?

1 reference

12 December 2020

Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity

1 reference

12 December 2020

Diet, diabetes and schizophrenia: review and hypothesis.

1 reference

12 December 2020

Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy.

1 reference

12 December 2020

The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro

1 reference

12 December 2020

S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in compar

1 reference

12 December 2020

The role of 5-HT2A receptor and 5-HT2A/5-HT1A receptor interaction in the suppression of catalepsy.

1 reference

12 December 2020

Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy

1 reference

12 December 2020

Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

1 reference

12 December 2020

Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2Asites for PCP-induced locomotion in the rat

1 reference

12 December 2020

LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia

1 reference

12 December 2020

Behavioral effects of 8-OH-DPAT in single and repeated haloperidol injected rats.

1 reference

12 December 2020

Azapirones for generalized anxiety disorder

1 reference

12 December 2020

An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression

1 reference

12 December 2020

Agonist-stimulated GTPγ[35S] binding to 5-HT1A receptors in human post-mortem brain

1 reference

12 December 2020

The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.

1 reference

12 December 2020

A search for colocalization of serotonin 5-HT2A and 5-HT1A receptors in the rat medial prefrontal and entorhinal cortices--immunohistochemical studies

1 reference

12 December 2020

Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide

1 reference

12 December 2020

The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats

1 reference

12 December 2020

Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)

1 reference

12 December 2020

Identifying psychophysiological risk for psychopathology: examples from substance abuse and schizophrenia research.

1 reference

12 December 2020

Use of buspirone in the treatment of schizophrenia

1 reference

12 December 2020

The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens

1 reference

12 December 2020

S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a mul

1 reference

12 December 2020

Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex.

1 reference

12 December 2020

Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties

1 reference

12 December 2020

S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine a

1 reference

12 December 2020

The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity

1 reference

12 December 2020

Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.

1 reference

12 December 2020

Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients

1 reference

12 December 2020

Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.

1 reference

12 December 2020

Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia

1 reference

12 December 2020

Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.

1 reference

12 December 2020

The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.

1 reference

12 December 2020

An open trial of buspirone added to neuroleptics in schizophrenic patients.

1 reference

12 December 2020

Role of 5-HT1A receptors in the ability of mixed 5-HT1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats

1 reference

12 December 2020

10.1007/S00213-011-2247-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394633%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

25 January 2020

0 references

1 reference